News
Health Bureau backs better private healthcare price transparency
Health Bureau backs better private healthcare price transparency
Public hospitals handle the majority of inpatient and specialist care.
Wharf REIC’s net profit drops 81% to $891m in 2024
Basic earnings per share fell to $0.29.
Gleneagles Hospital Hong Kong to offer histotripsy for liver cancer
The service is expected to begin by the end of March.
Gov't rejects S&P’s claim of housing oversupply
It pointed out that housing demand is currently keen.
Delivery Hero to acquire Deliveroo’s Hong Kong assets
Its customers and couriers will now be redirected to foodpanda.
HashKey Exchange, B2C2 partner to boost fiat trading
This aims to drive market efficiency.
Stock Exchange of Thailand added to HKEX's recognised stock list
The move is expected to boost cross-border investment and increase exposure to ASEAN enterprises in Hong Kong’s financial markets.
Digital wealth advisory Endowus introduces OTP verification
There’s also a Whatsapp OTP verification for customers logging in overseas.
Hongkong Land widens loss by 138% in FY2024
It was due to non-cash provisions from the Chinese mainland build-to-sell business.
Manulife extends partnership with CUHK Medical Centre
The collaboration will include histotripsy under the ‘Medical Professional Support Service.’
Gleneagles, Fosun Health partner for enhanced medical integration in GBA
Key areas include patient referrals, specialist services, and healthcare management.
Gov’t to introduce driving licence bill
The bill proposes to amend the Road Traffic Ordinance and related legislation.
Gov't to factor in Consumer Council report in healthcare price transparency
The Council made five key recommendations to improve price transparency.
Asset growth, connectivity drive HK’s capital markets in 2024
ETF's daily turnover surged by 35% YoY to $18.9b.
Gov’t alerts public of fraudulent entity
Linkbex made false claims of its affiliation with seven SFC-licensed corporations.
TSIT Wing International’s profit grows 21% in FY2024
The company’s proposed final dividend stood at $0.0216.
CK Life Sciences to post $126.6m loss in 2024
It was due to increased research and development investments.
Read Here
Advertise
Sign Up
Commentary
Why Hong Kong's carried interest reform matters, and why it isn't a zero-sum play
Medical centre expansion in Hong Kong: How to choose the right location
The Claude ban is a crash course in digital resilience — and that’s good for Hong Kong bankers